Table 1 Baseline characteristics of the development cohort and validation cohort
|  | Development (n = 844) | Validation (n = 428) | p |
|---|---|---|---|
Age, y | 66.02 (10.44) | 65.96 (11.02) | 0.921 |
Female, n (%) | 204 (24.2) | 82 (19.2) | 0.051 |
Weight, n | 63.48 (10.10) | 62.62 (10.49) | 0.361 |
SBP, mmHg | 127.66 (20.48) | 128.85 (20.78) | 0.329 |
DBP, mmHg | 74.30 (12.08) | 74.92 (12.31) | 0.385 |
HR, bpm | 75.61 (13.73) | 75.60 (14.41) | 0.989 |
Medical history | |||
 CKD, n (%) | 251 (29.7) | 105 (24.5) | 0.059 |
 AMI, n (%) | 378 (45.1) | 202 (47.3) | 0.495 |
 Hypertension, n (%) | 494 (58.5) | 250 (58.5) | 1 |
 Pre-hypotension, n (%) | 13 (1.5) | 9 (2.1) | 0.621 |
 Hyperlipidemia, n (%) | 99 (11.7) | 40 (9.3) | 0.233 |
 Anemia, n (%) | 346 (41.6) | 179 (42.2) | 0.878 |
 DM, n (%) | 219 (25.9) | 96 (22.5) | 0.2 |
 CHF, n (%) | 198 (23.6) | 87 (20.4) | 0.227 |
 LVEF, n | 56.28 (12.98) | 55.39 (12.16) | 0.262 |
 NYHA | 1.92 (0.76) | 1.87 (0.67) | 0.317 |
Laboratory examination | |||
 eGFR, mL/min/1.73 m2 | 72.30 (22.57) | 73.42 (21.68) | 0.395 |
 Scr, μmol/L | 103.03 (59.22) | 100.22 (40.16) | 0.379 |
 ALB, g/l | 31.59 (2.72) | 31.60 (2.74) | 0.96 |
 Lpa, mg/dl | 34.55 (36.49) | 34.10 (38.28) | 0.849 |
 BUN, mg/dl | 5.61 (3.03) | 5.67 (3.02) | 0.75 |
 Na, mmol/L | 138.82 (3.40) | 138.42 (3.43) | 0.097 |
 K, mmol/L | 3.74 (0.46) | 3.72 (0.43) | 0.547 |
Medications | |||
 Metformin, n (%) | 31 (3.7) | 16 (3.7) | 1 |
 ACEI/ARB, n (%) | 735 (87.1) | 388 (90.7) | 0.075 |
 Diuretics, n (%) | 187 (22.2) | 97 (22.6) | 0.603 |
 Beta blocker, n (%) | 678 (80.3) | 362 (84.6) | 0.076 |
Procedure | |||
 Contrast volume, mL | 133.99 (66.22) | 131.97 (63.40) | 0.603 |
 IABP, n (%) | 43 (5.1) | 18 (4.2) | 0.574 |
 Hydration volume, mL | 874.12 (516.30) | 816.60 (418.54) | 0.047 |
Other | |||
 CA-AKI, n (%) | 71 (8.4) | 48 (11.2) | 0.129 |
 Mehran score | 5.75 (4.74) | 5.25 (4.61) | 0.075 |